702 results on '"Carrier, Lucie"'
Search Results
2. Western diet triggers cardiac dysfunction in heterozygous Mybpc3-targeted knock-in mice: A two-hit model of hypertrophic cardiomyopathy
Catalog
Books, media, physical & digital resources
3. Abstract 12927: Impact of AAV-MYBPC3 Gene Transfer on Heart Structure and Function in Human and Mouse Models of Hypertrophic Cardiomyopathy
4. The detyrosination/re-tyrosination cycle of tubulin and its role and dysfunction in neurons and cardiomyocytes
5. Chronic Activation of Tubulin Tyrosination Improves Heart Function.
6. Cas9-expressing chickens and pigs as resources for genome editing in livestock
7. Ouabain worsens diastolic sarcomere length in myocytes from a cardiomyopathy mouse model
8. Translational investigation of electrophysiology in hypertrophic cardiomyopathy
9. Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
10. FYCO1 Regulates Cardiomyocyte Autophagy and Prevents Heart Failure Due to Pressure Overload In Vivo
11. Targeting the population for gene therapy with MYBPC3
12. Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover.
13. Autophagy in cardiomyopathies
14. Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy
15. Arterial Spin Labeling and T2* Mapping Detect Early Changes in Hypertrophic Cardiomyopathy
16. Targets for therapy in sarcomeric cardiomyopathies
17. Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy
18. Mechanistic role of the CREB-regulated transcription coactivator 1 in cardiac hypertrophy
19. RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy.
20. Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes—a systematic review
21. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy
22. Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy
23. Imaging of existing and newly translated proteins elucidates mechanisms of sarcomere turnover
24. EGFR/IGF1R Signaling Modulates Relaxation in Hypertrophic Cardiomyopathy
25. Generation of a homozygous CRYAB p.Arg120Gly mutant (UKEi001-A-1) from a human iPSC line
26. Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes
27. Nitro-fatty acids suppress ischemic ventricular arrhythmias by preserving calcium homeostasis
28. Kiosk 9R-TB-03 - Arterial Spin Labeling and T2* Mapping Detect Early Changes in Hypertrophic Cardiomyopathy
29. Depletion of Vasohibin 1 Speeds Contraction and Relaxation in Failing Human Cardiomyocytes
30. Animal models and animal-free innovations for cardiovascular research
31. Reducing microtubule detyrosination improves heart function in HCM mice and human iPSC-engineered heart tissues
32. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue
33. Making Sense of Inhibiting Nonsense in Hypertrophic Cardiomyopathy
34. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue
35. Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy
36. The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation
37. I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model
38. Hypertrophic Cardiomyopathy
39. Modelling LMNA-cardiomyopathy with patient-specific human iPSC-derived engineered heart tissue and a partial rescue by gene replacement therapy
40. A human CRYABR120G Desmin-related cardiomyopathy cellular model
41. Modelling aberrant microtubule De-/Tyrosination in HiPSC-derived engineered heart tissues
42. Functional characterisation of a patient-derived laminopathy model in human engineered heart tissues recapitulates fibrosis and mechanical decoupling defect
43. Investigating the molecular disease mechanisms of the human p.G592R PRKD1 mutation in human induced pluripotent stem cell-derived cardiomyocytes
44. Ubiquitin-proteasome system and hereditary cardiomyopathies
45. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets
46. ACTN2 Mutant Causes Proteopathy in Human iPSC-Derived Cardiomyocytes
47. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice
48. The expression of podocyte-specific proteins in parietal epithelial cells is regulated by protein degradation
49. Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP)-mediated Calcium Signaling and Arrhythmias in the Heart Evoked by β-Adrenergic Stimulation
50. Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.